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 1. Ethics 
 
The IMPROVE study was funded by the Vth European Union (EU) programme, which 
involves seven recruiting centres in five European countries: Finland, France, Italy, the Netherlands, 
and Sweden. The study was designed in accordance with the rules of Good Clinical Practice (GCP), 
and with the ethical principles established in the Declaration of Helsinki. The study was approved 
by the IRB at each one of the seven recruiting centers: (1) the Regional Ethics Review Board at 
Karolinska Institutet, Stockholm Sweden, (2) IRB at the Groupe Hôpitalier Pitie-Salpetriere, Paris, 
France, (3) the IRB Comitato Etico delle Aziende Sanitarie della regione Umbria, Perugia and (4) 
the IRB at the Ospedale Niguarda Ca´Granda, Milano, both in Italy, (5) the IRB at the University 
Hospital Groningen, Groningen, the Netherlands, (6) the IRB Hospital District of Northern Savo 
and (7) and the IRB at University of Eastern Finland, both in Kuopio, Finland. Each participant 
provided two different written consents one for general participation in the study and one for 
genotyping. 
  
2.1 Supplementary Figure I. Flowchart summarizing the IMPROVE study participants included in 
the present study. 
 
 
2.2 Supplementary Figure II. Manhattan plot sumaring the results of the association analysis 
 
 
 
